[{"id":"2dfeb986-6721-4504-befe-6a96df34412d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05239910","created_at":"2022-02-15T16:53:13.149Z","updated_at":"2024-07-02T16:36:02.370Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL","source_id_and_acronym":"NCT05239910","lead_sponsor":"Rhizen Pharmaceuticals SA","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • tenalisib (RP6530)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2022-10-17"}]